Implanet: Convocation to the General Shareholders’ Meeting on June 11, 2019 at 2:00 pm

BORDEAUX, France & BOSTON–(BUSINESS WIRE)–Regulatory News:

IMPLANET (Paris:ALIMP) (OTCQX:IMPZY) (Euronext Growth: ALIMP,
FR0010458729, eligible for PEA-PME equity savings plans), a medical
technology company specializing in vertebral and knee surgery implants,
informs its shareholders that a General Shareholders’ meeting is held
on June 11, 2019 at 2:00 pm at the Company’s registered office located
Allée F. Magendie – Technopole Bordeaux Montesquieu – 33650 Martillac –
France.

The documents related to the General Meeting are available on the
Company’s website (https://www.Implanet-invest.com/assemblee-generale)
by May 24, 2019.

The participation of Implanet’s shareholders is decisive to obtain
the quorum necessary to hold this General Meeting and vote on company’s
resolutions.

The shareholders can vote:

• by internet via the Votaccess service,
• by absentee voting,
• by proxy voting,
• or attend physically the General Meeting.

A guide contained in a new Letter To Shareholders – May, 2019 outlines
how to vote, and notably how to vote by internet (only in French). You
can download it here.
It was also posted on Implanet’s website on May 24, 2019. The
shareholders can also contact the Investor Relations team by email for
any question concerning the ways of voting: implanet@newcap.eu

If the quorum is not reached following the first convocation, a second
meeting will be held on June 25, 2019 at 2:00 pm at the Company’s
registered office located Allée F. Magendie – Technopole Bordeaux
Montesquieu – 33650 Martillac – France.

About Implanet
Founded in 2007, Implanet is a medical
technology company that manufactures high-quality implants for
orthopedic surgery. Its flagship product, the Jazz® latest-generation
implant, aims to treat spinal pathologies requiring vertebral fusion
surgery Implanet’s tried-and-tested orthopedic platform, which is based
on perfect control over the traceability of its products, provides it
with a proven ability to promote this innovation. Protected by four
families of international patents, JAZZ® has obtained 510(k) regulatory
clearance from the Food and Drug Administration (FDA) in the United
States and the CE mark and the Anvisa authorization in Brazil. Implanet
employs 38 staff and recorded 2018 sales of €6.7 million. For further
information, please visit www.Implanet.com.
Based near Bordeaux in France, Implanet established a US subsidiary in
Boston in 2013. Implanet is listed on Euronext™ Growth market in Paris.
The Company would like to remind that the table for monitoring the
equity line (BEOCABSA, OCA, BSA) and the number of shares outstanding,
is available on its website: http://www.implanet-invest.com/suivi-des-actions-80

Contacts

IMPLANET
Ludovic Lastennet, CEO
David Dieumegard, CFO
Tél.:
+33(0)5 57 99 55 55
investors@Implanet.com

NewCap
Investor Relations
Sandrine Boussard-Gallien
Tél.:
+33(0)1 44 71 94 94
Implanet@newcap.eu

NewCap
Media Relations
Nicolas Merigeau
Tél.: +33(0)1 44
71 94 94
Implanet@newcap.eu